Cover Image
市場調查報告書

CalAsia Pharmaceuticals, Inc. - 產品平台分析

CalAsia Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256087
出版日期 內容資訊 英文 21 Pages
訂單完成後即時交付
價格
Back to Top
CalAsia Pharmaceuticals, Inc. - 產品平台分析 CalAsia Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年04月29日 內容資訊: 英文 21 Pages
簡介

CalAsia Pharmaceuticals, Inc. 是藉由技術開發及實踐來研發藥性小分子的製藥公司。該公司同時也主導許多中樞神經系統/全身性腫瘤、感染疾病、以及變性中樞神經系統障礙相關治療藥的藥物研發計劃。

本報告提供CalAsia Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

CalAsia Pharmaceuticals, Inc.的基本資料

CalAsia Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

CalAsia Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

CalAsia Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

CalAsia Pharmaceuticals, Inc.:開發中產品概況

  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

CalAsia Pharmaceuticals, Inc.:藥物簡介

  • Small Molecule to Inhibit Hsp90 for Central Nervous System Disorders
  • Small Molecules for Non-Surgical Cataracts and Multiple Sclerosis
  • Small Molecules to Inhibit Hsp90 Alpha and TRAP1 for Brain Cancer
  • Small Molecules to Inhibit Hsp90 for Neurofibromatosis Type 2

CalAsia Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

CalAsia Pharmaceuticals, Inc.:暫停中的計劃

CalAsia Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07027CDB

Summary

Global Markets Direct's, 'CalAsia Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the CalAsia Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CalAsia Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CalAsia Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CalAsia Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CalAsia Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate CalAsia Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CalAsia Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CalAsia Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CalAsia Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CalAsia Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CalAsia Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CalAsia Pharmaceuticals, Inc. Snapshot
    • CalAsia Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • CalAsia Pharmaceuticals, Inc. - Research and Development Overview
  • Key Therapeutic Areas
  • CalAsia Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products Glance
    • CalAsia Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • CalAsia Pharmaceuticals, Inc. - Drug Profiles
    • Small Molecule to Inhibit Hsp90 for Central Nervous System Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Non-Surgical Cataracts and Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Hsp90 and TRAP1 for Brain Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Hsp90 for Neurofibromatosis Type 2
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CalAsia Pharmaceuticals, Inc. - Pipeline Analysis
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products by Target
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • CalAsia Pharmaceuticals, Inc. - Dormant Projects
  • CalAsia Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CalAsia Pharmaceuticals, Inc., Key Information
  • CalAsia Pharmaceuticals, Inc., Key Facts
  • CalAsia Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • CalAsia Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • CalAsia Pharmaceuticals, Inc. - Discovery, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • CalAsia Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • CalAsia Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top